KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Asset Writedowns and Impairment: 2015-2019

Historic Asset Writedowns and Impairment for Arbutus Biopharma (ABUS) over the last 5 years, with Dec 2019 value amounting to $43.8 million.

  • Arbutus Biopharma's Asset Writedowns and Impairment rose 195.97% to $43.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $196.3 million, marking a year-over-year increase of 27.90%. This contributed to the annual value of $43.8 million for FY2019, which is 195.97% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Asset Writedowns and Impairment of $43.8 million as of FY2019, which was up 195.97% from $14.8 million recorded in FY2018.
  • Arbutus Biopharma's Asset Writedowns and Impairment's 5-year high stood at $253.2 million during FY2016, with a 5-year trough of $14.8 million in FY2018.
  • For the 3-year period, Arbutus Biopharma's Asset Writedowns and Impairment averaged around $33.1 million, with its median value being $40.8 million (2017).
  • In the last 5 years, Arbutus Biopharma's Asset Writedowns and Impairment soared by 549.11% in 2016 and then tumbled by 83.89% in 2017.
  • Arbutus Biopharma's Asset Writedowns and Impairment (Yearly) stood at $39.0 million in 2015, then spiked by 549.11% to $253.2 million in 2016, then plummeted by 83.89% to $40.8 million in 2017, then crashed by 63.70% to $14.8 million in 2018, then surged by 195.97% to $43.8 million in 2019.